See more : MIRAIT ONE Corporation (1417.T) Income Statement Analysis – Financial Results
Complete financial analysis of Theravance Biopharma, Inc. (TBPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theravance Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kawai Musical Instruments Manufacturing Co., Ltd. (7952.T) Income Statement Analysis – Financial Results
- Goodfood Market Corp. (GDDFF) Income Statement Analysis – Financial Results
- Premier Financial Bancorp, Inc. (PFBI) Income Statement Analysis – Financial Results
- Oshidori International Holdings Limited (0622.HK) Income Statement Analysis – Financial Results
- Anhui Annada Titanium Industry Co., Ltd. (002136.SZ) Income Statement Analysis – Financial Results
Theravance Biopharma, Inc. (TBPH)
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 57.42M | 51.35M | 55.31M | 71.86M | 73.41M | 60.37M | 15.39M | 48.65M | 42.13M | 11.69M | 226.00K | 130.15M | 14.85M |
Cost of Revenue | 40.62M | 6.59M | 7.29M | 260.95M | 219.25M | 715.00K | 6.03M | 2.89M | 4.66M | 4.06M | 120.58M | 114.00M | 3.84M |
Gross Profit | 16.80M | 44.76M | 48.03M | -189.10M | -145.83M | 59.66M | 9.36M | 45.75M | 37.47M | 7.63M | -120.35M | 16.15M | 11.01M |
Gross Profit Ratio | 29.26% | 87.17% | 86.83% | -263.16% | -198.65% | 98.82% | 60.81% | 94.05% | 88.95% | 65.28% | -53,253.54% | 12.41% | 74.12% |
Research & Development | 40.62M | 63.39M | 193.66M | 260.95M | 219.25M | 201.35M | 173.89M | 141.71M | 129.17M | 168.52M | 120.58M | 114.00M | 98.85M |
General & Administrative | 65.00M | 59.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 5.10M | 8.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 70.10M | 67.07M | 99.30M | 108.66M | 106.08M | 97.06M | 95.59M | 84.51M | 90.20M | 71.65M | 35.93M | 25.73M | 21.50M |
Other Expenses | 0.00 | 0.00 | 0.00 | -1.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 113.46M | 130.47M | 292.95M | 369.61M | 325.33M | 298.41M | 269.48M | 226.22M | 219.37M | 240.17M | 156.51M | 139.72M | 120.35M |
Cost & Expenses | 113.46M | 130.47M | 292.95M | 369.61M | 325.33M | 299.12M | 275.51M | 229.12M | 224.03M | 244.23M | 156.51M | 139.72M | 124.19M |
Interest Income | 9.12M | 8.55M | 1.11M | 2.83M | 8.40M | 11.97M | 4.96M | 1.31M | 631.00K | 1.87M | 0.00 | 0.00 | 0.00 |
Interest Expense | 2.35M | 6.37M | 46.89M | 44.59M | 31.86M | 10.48M | 8.55M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 6.05M | 6.59M | 7.29M | 6.64M | 6.52M | 3.17M | 4.03M | 3.12M | 2.99M | 2.66M | 2.65M | 3.25M | 3.84M |
EBITDA | -40.87M | -79.86M | -249.39M | -294.00M | -203.29M | -212.44M | -259.14M | -176.04M | -178.77M | -228.01M | -153.63M | -6.32M | -105.49M |
EBITDA Ratio | -71.17% | -137.45% | -239.64% | -315.19% | -285.80% | -357.14% | -1,658.42% | -368.27% | -424.70% | -1,989.55% | -67,978.32% | -4.86% | -710.19% |
Operating Income | -56.04M | -91.96M | -257.78M | -297.76M | -251.92M | -238.75M | -260.12M | -180.47M | -181.90M | -232.54M | -156.28M | -9.58M | -109.34M |
Operating Income Ratio | -97.58% | -179.09% | -466.06% | -414.37% | -343.14% | -395.48% | -1,690.65% | -370.96% | -431.80% | -1,989.55% | -69,152.21% | -7.36% | -736.06% |
Total Other Income/Expenses | 6.77M | -858.00K | -7.44M | 11.22M | 10.24M | 12.67M | -11.59M | -92.00K | 631.00K | 1.87M | 0.00 | 0.00 | 0.00 |
Income Before Tax | -49.27M | -92.82M | -199.58M | -286.54M | -241.68M | -226.09M | -271.71M | -180.56M | -181.27M | -230.67M | -156.28M | -9.58M | -109.34M |
Income Before Tax Ratio | -85.80% | -180.76% | -360.83% | -398.76% | -329.20% | -374.50% | -1,765.96% | -371.15% | -430.30% | -1,973.60% | -69,152.21% | -7.36% | -736.06% |
Income Tax Expense | 5.92M | 9.00K | -151.00K | -8.52M | -5.22M | -10.56M | 13.69M | 10.11M | 951.00K | 6.36M | 0.00 | 0.00 | 0.00 |
Net Income | -55.19M | -92.82M | -199.43M | -278.02M | -236.46M | -215.52M | -285.41M | -190.67M | -182.22M | -237.04M | -156.28M | -9.58M | -109.34M |
Net Income Ratio | -96.11% | -180.78% | -360.55% | -386.90% | -322.08% | -357.01% | -1,854.97% | -391.94% | -432.56% | -2,028.05% | -69,152.21% | -7.36% | -736.06% |
EPS | -1.00 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.92 | -0.30 | -3.43 |
EPS Diluted | -1.00 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.84 | -0.30 | -3.43 |
Weighted Avg Shares Out | 55.30M | 73.59M | 69.46M | 62.35M | 55.61M | 53.97M | 52.35M | 44.71M | 34.15M | 31.76M | 31.74M | 31.74M | 31.90M |
Weighted Avg Shares Out (Dil) | 55.30M | 73.59M | 69.46M | 62.35M | 55.61M | 53.97M | 52.35M | 44.71M | 34.15M | 31.76M | 32.26M | 32.26M | 31.90M |
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround
Theravance Biopharma shares down on lung disease trial failure
Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
7 Short-Squeeze Stocks That Are Screaming for Speculation
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?
Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System
Source: https://incomestatements.info
Category: Stock Reports